- Home
- SUPN vs GNW Comparison
SUPN vs GNW Comparison
Compare SUPN & GNW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SUPN | GNW |
|---|---|---|
| Founded | 2005 | 1871 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Life Insurance |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.8B | 3.3B |
| IPO Year | 2010 | 2004 |
Fundamental Metrics
Financial Performance| Metric | SUPN | GNW |
|---|---|---|
| Price | $54.18 | $8.44 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 1 |
| Target Price | ★ $61.60 | $10.00 |
| AVG Volume (30 Days) | 781.0K | ★ 3.3M |
| Earning Date | 05-21-2026 | 05-22-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 6500.00 | 325.00 |
| EPS | N/A | ★ 0.53 |
| Revenue | $392,755,000.00 | ★ $7,295,000,000.00 |
| Revenue This Year | $8.18 | N/A |
| Revenue Next Year | $22.15 | N/A |
| P/E Ratio | ★ N/A | $16.28 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $29.16 | $5.99 |
| 52 Week High | $59.68 | $9.28 |
Technical Indicators
Market Signals| Indicator | SUPN | GNW |
|---|---|---|
| Relative Strength Index (RSI) | 60.66 | 43.18 |
| Support Level | $47.95 | $8.20 |
| Resistance Level | $57.65 | $8.80 |
| Average True Range (ATR) | 2.13 | 0.26 |
| MACD | 0.49 | -0.04 |
| Stochastic Oscillator | 46.18 | 27.23 |
Price Performance
Historical ComparisonAbout SUPN Supernus Pharmaceuticals Inc.
Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, and Osmolex ER.
About GNW Genworth Financial Inc
Genworth Financial Inc is a diversified insurance holding company that provides various mortgage and life insurance products. The company has three main operating business segments: Enact, Life and Annuities segment and Long-Term Care Insurance. The company's product portfolio includes various financial products such as traditional life insurance, mortgage insurance, fixed annuities, and variable annuities. Majority of the revenue is generated by the Enact segment. The company earns maximum of its revenue in the United States.